Open-label, drug-drug interaction study between the HIV-1 maturation inhibitor GSK3640254 and a metabolic probe cocktail in healthy participants.

Ying Zhang,Mark Johnson,Samit Joshi,Parto Yazdani,Joyce Zhan,Bo Wen,Veronica Bainbridge,Martin Gartland,Max Lataillade

British journal of clinical pharmacology（2023）

引用 2|浏览5

暂无评分

摘要

Co-administration of GSK'254 with a metabolic probe cocktail in healthy participants indicated very low risk of clinically relevant effect on PK of any substrates or associated metabolites. No new safety/tolerability concerns were identified. These results support ongoing phase IIb and planned phase III studies of GSK'254 in people living with HIV-1.

查看译文

关键词

antiretroviral therapy,cytochrome P450,drug transporters,pharmacodynamics,pharmacokinetics

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要